FIELD: chemistry; pharmaceuticals.
SUBSTANCE: invention relates to the treatment of fungal infections. A method of treating a fungal infection being a mold infection caused by the following fungi: Aspergillus spp., Scedosporium spp., Fusarium spp. or Mucorales or a combination thereof is disclosed, the said method comprises administering a therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the therapeutically effective amount of Compound 1 provides a stable area over a 24 hour period under the concentration-time curve (AUC0-24) of Compound 1A at subject exceeding 200 mcg⋅h/ml of Compound 1A, and administration of Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof to a subject comprises a treatment regimen comprising daily administration of Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof for a period of at least 4 weeks, wherein the regimen treatment includes a loading dose of Compound 1 or its pharmaceutically acceptable salt, solvate or hydrate and a maintenance dose of Compound 1 or its pharmaceutically acceptable salt, solvate or hydrate, where the loading dose of Compound 1 or its pharmaceutically acceptable salt, solvate or hydrate is 2,000 mg and where the maintenance the dose includes a single daily administration of 600 to 1,500 mg of Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
EFFECT: use of the invention provides effective treatment of fungal infections caused by Aspergillus spp., Scedosporium spp., Fusarium spp. or Mucorales or a combination thereof.
32 cl, 3 tbl, 3 ex
